Immunovant Stock Price Prediction

IMVT Stock  USD 18.37  0.42  2.24%   
At this time, the RSI of Immunovant's share price is approaching 48. This usually indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Immunovant, making its price go up or down.

Momentum 48

 Impartial

 
Oversold
 
Overbought
The successful prediction of Immunovant's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Immunovant, which may create opportunities for some arbitrage if properly timed.
Using Immunovant hype-based prediction, you can estimate the value of Immunovant from the perspective of Immunovant response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Immunovant to buy its stock at a price that has no basis in reality. In that case, they are not buying Immunovant because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Immunovant after-hype prediction price

    
  USD 18.52  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Immunovant Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunovant's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
16.5325.9529.35
Details
Naive
Forecast
LowNextHigh
14.6218.0221.41
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
17.8419.1520.45
Details

Immunovant After-Hype Price Prediction Density Analysis

As far as predicting the price of Immunovant at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Immunovant or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Immunovant, with the unreliable approximations that try to describe financial returns.
   Next price density   
JavaScript chart by amCharts 3.21.1518.5118.5118.5118.5218.5218.5218.5318.5318.53 Price after next news: 18.52 0.035179890.035179900.035179910.03517992
       Expected price to next headline  

Immunovant Estimiated After-Hype Price Volatility

In the context of predicting Immunovant's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Immunovant's historical news coverage. Immunovant's after-hype downside and upside margins for the prediction period are 15.12 and 21.92, respectively. We have considered Immunovant's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
18.37
18.52
After-hype Price
21.92
Upside
Immunovant is not too volatile at this time. Analysis and calculation of next after-hype price of Immunovant is based on 3 months time horizon.

Immunovant Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Immunovant is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunovant backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Immunovant, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.37 
3.37
 0.00  
  0.41 
0 Events / Month
11 Events / Month
Uncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
18.37
18.52
0.82 
0.00  
Notes

Immunovant Hype Timeline

Immunovant is currently traded for 18.37. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.41. Immunovant is anticipated to increase in value after the next headline, with the price projected to jump to 18.52 or above. The average volatility of media hype impact on the company the price is insignificant. The price appreciation on the next news is projected to be 0.82%, whereas the daily expected return is currently at -0.37%. The volatility of related hype on Immunovant is about 305.67%, with the expected price after the next announcement by competition of 17.96. Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next anticipated press release will be uncertain.
Check out Immunovant Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.
JavaScript chart by amCharts 3.21.1525.19STOK @ financeAKRO @ newsAMLX @ zacksPLRX @ gurufocusSTOK @ globenewswireMDGL @ thelincolnianonlineACLX @ financeDAWN @ zacksABUS @ thestarAPLS @ zacksDAWN @ businesswireACLX @ businesswireMDGL @ gurufocusAKRO @ seekingalphaACLX @ zacksBPMC @ gurufocusDAWN @ thelincolnianonlineABUS @ zacksAMLX @ financePLRX @ thelincolnianonlineBPMC @ MacroaxisInsiderAPLS @ financeAMLX @ insidermonkeyAKRO @ thelincolnianonlineETNB @ financeAMLX @ kalkinemediaDAWN @ newsPTGX @ newsLEGN @ zacksPTGX @ insidermonkeyLEGN @ gurufocusAPLS @ newsBPMC @ financeACLX @ newsABUS @ MacroaxisInsiderPTGX @ financeMDGL @ MacroaxisInsiderLEGN @ newsSTOK @ businesswirePLRX @ globenewswireSTOK @ gurufocusPTGX @ gurufocus17.89ABUS @ seekingalphaFebMar
JavaScript chart by amCharts 3.21.15JanFebMar

Immunovant Related Hype Analysis

Having access to credible news sources related to Immunovant's direct competition is more important than ever and may enhance your ability to predict Immunovant's future price movements. Getting to know how Immunovant's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Immunovant may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
ABUSArbutus Biopharma Corp(0.01)10 per month 2.15  0.08  4.25 (4.39) 12.89 
ARQTArcutis Biotherapeutics 0.00 0 per month 3.72  0.07  8.36 (6.52) 22.69 
LEGNLegend Biotech Corp(0.89)6 per month 2.57  0.04  6.15 (4.40) 14.84 
PTGXProtagonist Therapeutics 5.87 12 per month 2.45  0.07  3.46 (3.69) 50.66 
ISEEIVERIC Bio 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
AKROAkero Therapeutics 0.30 9 per month 2.79  0.09  4.92 (5.05) 104.81 
MDGLMadrigal Pharmaceuticals(25.64)8 per month 3.96  0.05  7.64 (5.66) 23.14 
APLSApellis Pharmaceuticals 0.79 10 per month 0.00 (0.12) 4.11 (4.33) 20.77 
ETNB89bio Inc 0.04 12 per month 4.56  0.04  10.74 (8.98) 38.69 
PLRXPliant Therapeutics 0.19 9 per month 0.00 (0.16) 10.39 (14.98) 80.84 
ACLXArcellx 1.03 9 per month 0.00 (0.02) 4.79 (5.21) 10.80 
STOKStoke Therapeutics 0.02 7 per month 0.00 (0.12) 7.03 (9.08) 20.29 
BPMCBlueprint Medicines Corp 0.94 11 per month 2.51  0.02  5.87 (3.96) 26.30 
AMLXAmylyx Pharmaceuticals 0.21 7 per month 0.00 (0) 7.20 (9.09) 21.45 
KRTXKaruna Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
DAWNDay One Biopharmaceuticals(0.49)8 per month 0.00 (0.14) 6.36 (6.67) 22.86 

Immunovant Additional Predictive Modules

Most predictive techniques to examine Immunovant price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Immunovant using various technical indicators. When you analyze Immunovant charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Immunovant Predictive Indicators

The successful prediction of Immunovant stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Immunovant, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Immunovant based on analysis of Immunovant hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Immunovant's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Immunovant's related companies.

Story Coverage note for Immunovant

The number of cover stories for Immunovant depends on current market conditions and Immunovant's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Immunovant is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Immunovant's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Immunovant Short Properties

Immunovant's future price predictability will typically decrease when Immunovant's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Immunovant often depends not only on the future outlook of the potential Immunovant's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunovant's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding138.1 M
Cash And Short Term Investments635.4 M

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
PricesInvestor S…